A randomised, controlled, double blind study to assess mechanistic effects of combination therapy of dapagliflozin with exenatide QW versus dapagliflozin alone in obese patients with type 2 diabetes mellitus (RESILIENT): study protocol

A randomised, controlled, double blind study to assess mechanistic effects of combination therapy of dapagliflozin with exenatide QW versus dapagliflozin alone in obese patients with type 2 diabetes mellitus (RESILIENT): study protocol

Introduction The newer glucose-lowering therapies for type 2 diabetes (T2D), the glucagon-like peptide-1 receptor agonists (GLP1-RAs) and the sodium-glucose co-transporter 2 inhibitors (SGLT2i), have additional clinical benefits beyond improving glycaemic control; promoting weight loss, addressing a...

Full description

Bibliographic Details
Main Authors: Emily Brown, Victoria S Sprung, Graham J Kemp, John PH Wilding, Malcolm Burgess, Daniel J Cuthbertson, A Margot Umpleby, Jason C G Halford, Andrej Stancak, Moon M Wilton, Joanne A Harrold, Elaine Howarth
Format: Article
Language:English
Published: BMJ Publishing Group 2021-07-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/11/7/e045663.full

Internet

https://bmjopen.bmj.com/content/11/7/e045663.full

Similar Items